scout
News|Videos|June 10, 2025

SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive CLL/SLL

Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent safety profile in patients with treatment-naïve CLL/SLL, including those with del(17p). Funding supported by BeOne Medicines USA, Inc. Content independently developed by OncLive.

Funding supported by BeOne Medicines USA, Inc. Content independently developed by OncLive.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME